Regulatory Pathways for Transcatheter Atrioventricular Valve Repair Devices: Strategic Considerations for FDA Premarket Approval

Read full text Summarise with VIRAT
Authors: Poojaben Raj, Deilin Shanu Dalmeida, Sneha Priya Murari, Peivand Pirouzi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Transcatheter atrioventricular valve repair devices represent an emerging therapeutic class addressing significant unmet needs in structural heart disease. These minimally invasive systems enable valve repair without open-heart surgery, offering treatment options for patients with severe valvular regurgitation who are at high surgical risk. As permanently implanted cardiac devices with potential for serious adverse outcomes in the event of malfunction, transcatheter valve repair systems are classified as Class III devices under the United States Food and Drug Administration's framework, requiring Premarket Approval (PMA) with comprehensive clinical evidence demonstrating safety and effectiveness. This article examines the regulatory considerations governing transcatheter valve repair device development, including classification rationale, applicable standards, clinical evidence requirements, and strategic pathways for market authorization. Global regulatory alignment, including Canadian Medical Device Licence Application (MDLA) requirements and international harmonization mechanisms, is discussed. The integration of structured project management practices throughout device development is emphasized as essential to navigating the complex regulatory pathway efficiently. Keywords: transcatheter valve repair, structural heart, Class III medical device, PMA, FDA, ISO 13485, ISO 14971, risk management, tricuspid regurgitation

Fields of Study & Subjects

Cardiac Valve Diseases and Treatments Healthcare Regulation Cardiac pacing and defibrillation studies

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
25 March 2026
Language
EN